Goldman Sachs Downgrades Sage Therapeutics to Neutral, Announces $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
Goldman Sachs analyst Salveen Richter has downgraded Sage Therapeutics from Buy to Neutral and set a price target of $22.

August 08, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics has been downgraded from Buy to Neutral by Goldman Sachs, with a new price target of $22.
The downgrade from Buy to Neutral by a major financial institution like Goldman Sachs indicates a less optimistic outlook for the company's stock. This could potentially lead to a decrease in the stock's price in the short term. The new price target of $22 also suggests that the analyst believes the stock is currently overvalued.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100